NasdaqGS:ANABBiotechs
Assessing AnaptysBio (ANAB) Valuation As It Shifts To A Royalty Focus After Spinning Off Operations
Spin-off reshapes AnaptysBio’s business model
AnaptysBio (ANAB) has completed the spin-off of First Tracks Biotherapeutics, shifting from running biopharma operations to managing royalty-focused collaborations around Jemperli with GSK and imsidolimab with Vanda.
The company now plans to operate as a virtual business, emphasizing streamlined staffing and expenses, with an explicit goal of protecting and returning collaboration-derived royalties to shareholders.
See our latest analysis for...